Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with Immune Checkpoint Blockade or Other Standard of Care Regimens in Patients with Solid Tumors

Trial Profile

An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with Immune Checkpoint Blockade or Other Standard of Care Regimens in Patients with Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Feb 2019

At a glance

  • Drugs Nivolumab (Primary) ; RP-1 (Primary)
  • Indications Bladder cancer; Malignant melanoma; Skin cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Replimune
  • Most Recent Events

    • 03 Jan 2019 According to a Replimune Group Inc. media release, data from the phase 1 portion of the study is expected to be presented at a medical conference in the second half of 2019.
    • 03 Jan 2019 According to a Replimune Group Inc. media release, the company has completed the enrollment in the phase 1 portion of the study and expects to initiate enrollment in the phase 2 portion of ths study in the first half of 2019 in four cohorts of approximately 30 patients each with melanoma, bladder cancer, microsatellite instability high cancers, and non-melanoma skin cancers.
    • 14 Nov 2018 According to an Replimune Group Inc. media release, combination phase of the first part of the clinical trial is expected to be underway in the U.S. and the U.K. by the year end and second part is on track to begin in the first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top